Sonnet BioTherapeutics Holdings Inc is a clinical-stage biopharmaceutical company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and... Sonnet BioTherapeutics Holdings Inc is a clinical-stage biopharmaceutical company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others. Show more
European Patent Office (EPO) grants EU Patent No. EP3583125 B1 covering the Company’s Fully Human Albumin Binding (FHAB®) domain fusion proteins In addition to the U.S. and EU, Sonnet’s global IP...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.075 | -4.43786982249 | 1.69 | 1.87 | 1.53 | 54458 | 1.65849971 | CS |
4 | -0.145 | -8.23863636364 | 1.76 | 2.05 | 1.44 | 192839 | 1.75383013 | CS |
12 | -1.395 | -46.3455149502 | 3.01 | 4.85 | 1.41 | 1147134 | 1.96647319 | CS |
26 | -4.5578 | -73.8368325557 | 6.1728 | 10.02 | 1.41 | 767221 | 2.77320216 | CS |
52 | -9.585 | -85.5803571429 | 11.2 | 18.7192 | 1.41 | 425777 | 3.74814697 | CS |
156 | -789.329 | -99.7958136101 | 790.944 | 1649.4016 | 1.41 | 1908004 | 550.86328735 | CS |
260 | -15324.465 | -99.9894624066 | 15326.08 | 39916.8 | 1.41 | 2280573 | 2543.98908774 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.